OncoMatch/Clinical Trials/NCT06370000
Oral Azacitidine in Transplant-Eligible Patients With Acute Myeloid Leukemia (AML) Suffering From Health-Inequality
Is NCT06370000 recruiting? Yes, currently enrolling (Jun 2026). This Phase 4 trial studies Oral Azacitidine for acute myeloid leukemia.
Treatment: Oral Azacitidine — Test feasibility of an oral maintenance strategy for transplant eligible AML patients in first CR who are medically underserved or have a disadvantage in the CDC SDOH domains
Check if I qualifyExtracted eligibility criteria
Treatments studied
Other
Cancer type
Acute Myeloid Leukemia
Biomarker criteria
Required: FLT3 wild-type
FLT3 negative AML
Excluded: FLT3 ITD mutation
FLT3 ITD
Excluded: FLT3 tyrosine kinase domain (TKD) mutation
tyrosine kinase domain (TKD) mutation
Performance status
ECOG 0–3(Limited self-care)
Prior therapy
Must have received: induction and consolidation
have completed induction and consolidation as defined by the treating physician
Cannot have received: oral azacitidine (oral azacitidine)
History of prior therapy with oral azacitidine
Cannot have received: stem cell transplant
Exception: within previous 3 months prior to initiation of study therapy
Stem cell transplant within previous 3 months prior to initiation of study therapy
Lab requirements
Kidney function
creatinine clearance (by cockroft-gault formula) greater than or equal to 29 ml/min
Liver function
total bilirubin and aspartate aminotransferase/ alanine transaminase (ast/alt) ≤ to institutional 2x upper limit of normal (except gilbert's syndrome, which may enroll if < 2x patient's baseline total bilirubin)
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- Virginia Commonwealth University · Richmond, Virginia
Showing up to 5 US sites.
See all sites on ClinicalTrials.gov →Frequently asked questions
Is NCT06370000 currently recruiting?
Yes, this trial is currently recruiting patients.
Are there prior therapy exclusions?
Yes. Prior oral azacitidine, stem cell transplant disqualifies patients from enrollment.
Does this trial require FLT3?
Yes, FLT3 wild-type is a required biomarker for enrollment.
Are patients with FLT3 alterations eligible?
No. FLT3 ITD mutation is an exclusion criterion.
Are patients with FLT3 alterations eligible?
No. FLT3 tyrosine kinase domain (TKD) mutation is an exclusion criterion.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages